Publikation
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03
Wissenschaftlicher Artikel/Review - 09.07.2020
Heil Joerg, Friedrichs Kay, Wojcinski Sebastian, Joos Sylvie, Paepke Stefan, Ditsch Nina, Rody Achim, Große Regina, van Mackelenbergh Marion, Reinisch Mattea, Karsten Maria, Golatta Michael, Bekes Inga, Malter Wolfram, Hackmann John, Pfob André, Sinn Hans-Peter, Rauch Geraldine, Bach Paul, Thomas Bettina, Schaefgen Benedikt, Kuemmel Sherko, Reimer Toralf, Hahn Markus, Thill Marc, Blohmer Jens-Uwe, RESPONDER Investigators
Bereiche
PubMed
DOI
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Kurzbeschreibung/Zielsetzung
OBJECTIVE
We evaluated the ability of minimally invasive, image-guided vacuum-assisted biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B).
SUMMARY BACKGROUND DATA
Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in up to 80% of women with breast cancer. In such cases, breast surgery, the gold standard for confirming pCR-B, may be considered overtreatment.
METHODS
This multicenter, prospective trial enrolled 452 women presenting with initial stage 1-3 breast cancer of all biological subtypes. Fifty-four women dropped out; 398 were included in the full analysis. All participants had an imaging-confirmed partial or complete response to NST and underwent study-specific image-guided VAB before guideline-adherent breast surgery. The primary endpoint was the false-negative rate (FNR) of VAB-confirmed pCR-B.
RESULTS
Image-guided VAB alone did not detect surgically confirmed residual tumor in 37 of 208 women [FNR, 17.8%; 95% confidence interval (CI), 12.8-23.7%]. Of these 37 women, 12 (32.4%) had residual DCIS only, 20 (54.1%) had minimal residual tumor (<5 mm), and 19 of 25 (76.0%) exhibited invasive cancer cellularity of ≤10%. In 19 of the 37 cases (51.4%), the false-negative result was potentially avoidable. Exploratory analysis showed that performing VAB with the largest needle by volume (7-gauge) resulted in no false-negative results and that combining imaging and image-guided VAB into a single diagnostic test lowered the FNR to 6.2% (95% CI, 3.4%-10.5%).
CONCLUSIONS
Image-guided VAB missed residual disease more often than expected. Refinements in procedure and patient selection seem possible and necessary before omitting breast surgery.